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Abstract
Similar to other mammalian viruses, the life cycle of hepatitis B virus (HBV) is heavily dependent 
upon and regulated by cellular (host) functions. These cellular functions can be generally placed in 
to two categories: (a) intrinsic host restriction factors and innate defenses, which must be evaded 
or repressed by the virus; and (b) gene products that provide functions necessary for the virus to 
complete its life cycle. Some of these functions may apply to all viruses, but some may be specific 
to HBV. In certain cases, the virus may depend upon the host function much more than does the 
host itself. Knowing which host functions regulate the different steps of a virus’ life cycle, can 
lead to new antiviral targets and help in developing novel treatment strategies, in addition to 
improving a fundamental understanding of viral pathogenesis. Therefore, in this review we will 
discuss known host factors which influence key steps of HBV life cycle, and further elucidate 
therapeutic interventions targeting host-HBV interactions.
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1. Introduction
There are currently seven medications approved by the United States (US) Food and Drug 
Administration (FDA) for management of chronic hepatitis B virus (HBV) infection, 
including two interferons (standard and PEGylated IFN-α) and five nucleos(t)ide analogue 
polymerase (pol) inhibitors (Belongia et al., 2009; Block et al., 2007, 2015). Although the 
treatments have provided hope to those affected and have demonstrated the potential of 
medical intervention, these drugs are all of limited value. They result in sustained benefit in 
fewer than half of those in whom they are given (Belongia et al., 2009). Moreover, they are 
limited by toxicity (in the case of the interferons) or development of drug resistance as in the 
case of the viral DNA polymerase inhibitors (Hoofnagle et al., 2007; Zoulim and Locarnini, 
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2009). Therefore, development of novel direct acting agents (DAAs) and host targeting 
agents (HTAs) against HBV infection is warranted to enrich the landscape of HBV 
antivirals.
This review will discuss about the host functions which are involved in the various steps of 
HBV life cycle, and further explain possibilities of exploitation of host factors in therapeutic 
intervention of HBV. We will focus on the constitutive host systems that regulate HBV, and 
then further sub divide these categories in to their component pathways. The “induced” 
systems, such as innate host defense systems that negatively influence the viral life cycle 
also represents an important biology, but will be only considered briefly, in the discussion. 
The challenges of toxicity and selectivity, associated with targeting host functions for 
antiviral purposes are especially important, and are also discussed.
2. Hepatitis B virus replication and disease
HBV causes acute and chronic infections. Acute HBV infection can be either asymptomatic 
or present with symptomatic acute hepatitis. Most adults infected with the virus recover, but 
~5% of infected adults and 90% of infected neonates fail to mount an immune response that 
clears the virus, and they develop a life-long chronic infection that may progress to chronic 
active hepatitis, cirrhosis, and primary hepatocellular carcinoma (HCC) (Block et al., 2003; 
El-Serag and Mason, 1999; Hoofnagle, 2004). Despite an effective prophylactic vaccine, it 
remains a major public health challenge. Between 250 and 290 million people are 
chronically infected with HBV worldwide which results in 1 million deaths per year 
(Razavi-Shearer et al., 2018).
HBV is liver tropic virus with a ~3 kb partially double stranded (ds) DNA genome that 
specifies only 7 viral proteins, which include DNA polymerase (Pol), capsid protein (Core), 
HBeAg (hepatitis B e antigen), X protein, and three envelope proteins: LHBs (L), MHBs 
(M) and SHBs (S) (Block et al., 2007). The polymerase gene product is the only enzyme 
encoded by HBV, thus, virus life cycle is heavily dependent on host or cellular factors. Host 
functions are involved in almost every step in the HBV life cycle, from entry to secretion 
(Block et al., 2007; Ganem and Prince, 2004; Watanabe et al., 2007). HBV uses multiple 
host factors for its replication, and the interplay between host functions and HBV leads to 
severe disease consequences. Outlining the host factors involved in the life cycle of HBV 
can provide new insight for discovery of anti-HBV therapies, in which drugs targeting 
cellular factors can be developed.
3. Viral binding and entry into hepatocytes
3.1. Biology of viral binding and entry in to hepatocytes
Host functions mediating binding and entry of HBV in to hepatocytes are illustrated in Fig. 
1. HBV initiates infection by binding to a low affinity receptor, a heparan sulfate 
proteoglycan (HSPG) through the infectivity determinant in the surface-exposed antigenic 
loop (AGL), a polypeptide present in the S domain common to all envelope proteins (Li and 
Tong, 2015; Schulze et al., 2007; Sureau and Salisse, 2013). Glypican-5 (GPC5), a protein 
associated with proteoglycans, has recently been reported to be involved in entry of HBV 
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and hepatitis delta virus (HDV, a satellite virus of HBV by using HBV envelope proteins for 
cell entry), providing further clarity on how HSPG mediate HBV entry (Verrier et al., 2016). 
Proteoglycan binding is followed by a more specific, and higher affinity, interaction of the 
N-terminal myristoylated peptide in the pre-S1 domain of L protein with the host cellular 
plasma membrane bearing Sodium Taurocholate Cotransporting Polypeptide (NTCP) 
receptor expressed by host SLC10A1 gene (Bruss et al., 1996; Hagenbuch and Meier, 1994; 
Ni et al., 2014; Yan et al., 2012). The NTCP receptor is on the sinusoidal plasma membrane. 
The normal physiological function of NTCP is to facilitate hepatocyte uptake of sodium 
dependent bile acids from the circulation (Stieger, 2011; Takeyama et al., 2010), and its 
expression is mostly liver specific (Hagenbuch and Meier, 1994). NTCP is itself highly 
regulated, and its abundance on the sinusoidal membrane changes with pathological and 
physiological conditions, varying with blood bile salt levels (Roma et al., 2008). HBV 
infection appears to result in alteration of bile metabolism. For example, the level of 
cholesterol 7α-hydroxylase (CYP7A1), the rate limiting step in bile acid synthesis from 
cholesterol, was reported to be significantly elevated in HBV infected murine system with 
humanized liver and in liver biopsies from infected people (Oehler et al., 2014), suggesting 
an interplay between HBV infection and cellular genes involved in NTCP and bile acid 
regulation. One question that remains is the extent to which other host receptor(s) and co-
receptor component(s), in addition to NTCP, and t the hepatocyte microenvironment or 
soluble blood components (as seen in Adenoviruses infecting liver (Morizono and Chen, 
2011; Shayakhmetov et al., 2005)) have an effect upon HBV entry into hepatocytes. 
Understanding of the entry process in depth will help us identify the target(s) for drug 
intervention against hepatitis B infection.
3.2. Therapeutic interference with HBV binding and entry by targeting host factors
HBV binding to its receptor on hepatocytes has been successfully used as an antiviral target. 
Briefly, as indicated in Fig. 1, the synthetic anti-lipopolysaccharide peptides (SALPs) inhibit 
HBV infection through binding to heparan sulfate moieties on the cell surface (Krepstakies 
et al., 2012). Myrcludex B is a HBV preS1-derived synthetic lipopoly-peptide that has been 
shown to specifically bind to NTCP and block de novo HBV infection and prevent 
intrahepatic viral spreading both in vitro and in vivo (Blank et al., 2016), and clinical trials 
to manage chronic HBV/HDV infection are well under way, and antiviral efficacy is being 
demonstrated (Bogomolov et al., 2016). Cyclosporin A (CsA) is an immunosuppressant that 
can directly bind to NTCP and interrupt the interaction between NTCP and the preS1 region 
(Watashi et al., 2014). Interestingly, the amino acid motifs of NTCP critical for HBV entry 
overlap with that for bile salts uptake by NTCP, and the inhibition of HBV entry by NTCP 
natural ligands has been observed in cell cultures (Yan et al., 2014). Furthermore, a tricyclic 
polyketide, vanitaracin A, has been shown to inhibit HBV and HDV entry by directly 
interacting with NTCP and inhibiting its transporter activity (Kaneko et al., 2015). 
Nonetheless, it is worth noting that certain CsA analogs that abrogate the 
immunosuppressive activity possess a stronger anti-HBV activity without interfering NTCP 
transporter function, perhaps through an allosteric mechanism (Shimura et al., 2017). 
Elucidation of the structure of preS1-NTCP complex will help to explain the exact mode of 
action of the identified HBV entry inhibitors.
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Inhibition of HBV entry can also be achieved by reducing the level of NTCP expression. 
The retinoic acid receptor (RAR) has been proposed to regulate the promoter activity of the 
human NTCP (hNTCP) gene and an RAR-selective antagonist, R041–5253 decreases 
cellular susceptibility to HBV infection by inhibiting hNTCP promoter activity (Tsukuda et 
al., 2015). The interleukin cytokine, IL-6, has also been found to regulate NTCP expression. 
Pretreatment of HepaRG cells with IL-6 led to 98% reduction in NTCP mRNA expression, 
along with an 80% decrease in NTCP-mediated taurocholate uptake and 90% inhibition of 
HBV entry (Bouezzedine et al., 2015). However, IL-6 is a proinflammatory cytokine and its 
over-use might lead to development of autoimmune diseases. Thus, proper dosage or 
endogenous induction level need to be identified that would minimize the side-effects in 
further development.
In addition, N-Myristoylation of the terminal glycine of the preS1 domain of the LHBs 
polypeptide is essential for virus infectivity and is a post-translational event, mediated by 
specific cell acetylases (N-myristoyltransferases), providing another host function that can 
serve as an antiviral target (Bruss et al., 1996; Gripon et al., 1995).
4. De-envelopment and translocation of the nucleocapsid to the nucleus
4.1. Biology of de-envelopment and antegrade transport of nucleocapsid to the nucleus
De-envelopment and transport of the virion to the nucleus, and capsid disassembly, are not 
well characterized for HBV, although host cellular factors and processes are clearly 
involved. Huang et al. used an immortalized human primary hepatocyte cell line, HuS-E/2, 
transduced with human telomerase reverse transcriptase (hTERT) and human papillomavirus 
E6E7 (HPV/E6E7), to show that clathrin-dependent endocytosis is critical for HBV 
infection through interaction of clathrin associated heavy protein and adaptor (AP-2) with 
the pre-S1 domain of L protein (Huang et al., 2012). Fig. 2 shows these steps. Following 
internalization of HBV virions, there is a Rab5-and Rab7-dependent transport through the 
late endosomal compartment (distinct from recycling endosomes) which is also important to 
the de-envelopment of capsid (Macovei et al., 2013). Functional caveolin-1 was shown to be 
necessary for productive HBV infection in HepaRG cells (Macovei et al., 2010). It is 
speculated that disulfide-reduction within the endosomal compartments is involved in the 
de-envelopment process as well (Feener et al., 1990; Ohgami et al., 2005). Nonetheless, de-
envelopment must occur and the de-enveloped virion cargo of partially double stranded viral 
DNA is delivered to the nucleus.
4.2. Therapeutic interference with de-envelopment and translocation to the nucleus
Given that there are many steps involved in the transport of nucleocapsids to the nucleus 
following entry, numerous host functions can be imagined as targets for antiviral 
intervention. For example, it has been reported that phosphorylation of the capsid induces 
exposure of nuclear localization signal (NLS) in the COOH-terminal portion of the core 
protein that allows core binding to the nuclear pore complex (NPC) by the importin- 
(karyopherin-) mediated pathway (Kann et al., 1999). Elevation of cell cAMP, and 
stimulation of protein kinase A (PKA) with glucagon has been reported to interfere with the 
transport of capsids to the nucleus, at least in duck hepatitis B virus (DHBV) systems, 
Mitra et al. Page 4
Antiviral Res. Author manuscript; available in PMC 2018 October 18.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
further highlighting the role of phosphorylation in the early steps of the viral life cycle (Hild 
et al., 1998). That said, the targets of PKA (presumably viral core or polymerase) have not 
been determined. Another cellular kinase candidate for core proteins is CDK2 (Ludgate et 
al., 2012).
As is true for most mammalian viruses, a role for microtubule-dependent transfer of the 
HBV capsid to the nucleus and a subsequent release of the viral genomes into the 
karyoplasm has also been observed (Schmitz et al., 2010). Thus, HBV nucleocapsids are 
transported to the nuclear periphery by mechanisms involving microtubules where the 
capsids bind to cellular importin α and β for nuclear transport (Rabe et al., 2006). In line 
with this, ivermectin, a specific inhibitor of importin α/β-mediated nuclear import, has been 
shown to inhibit HBV and other viruses (Longarela et al., 2013; Wagstaff et al., 2012). It has 
been reported that the nucleocapsid-importin complex arriving at the nuclear pore complex 
binds to nucleoporin 153, and probably other cell proteins followed by importin α and β 
dissociation by RanGTP and the release of viral DNA and capsid proteins into the 
nucleoplasm (Pante and Kann, 2002; Schmitz et al., 2010; Schneider et al., 2014). While 
various host cellular and nuclear machinery have been identified to be involved in de-
envelopment and entry of HBV genome into the nucleus, a detailed molecular mechanism is 
yet to be determined.
5. Deproteination of viral DNA and synthesis of cccDNA
5.1. Biology of deproteination of viral DNA and synthesis of cccDNA
Intact, enveloped virions, as bound to the NTCP receptor, contain “relaxed circular” (rc) 
DNA, which are incomplete double strands of the viral genome (Seeger and Mason, 2000). 
The “minus” strand (complimentary to the RNA) is nearly complete, but is covalently linked 
to the HBV polymerase (pol) at its 5′ end, and a short 8–9 nt terminal redundant sequence 
on both termini. Compared with the minus strand, the plus strand is several hundred 
nucleotides shorter at the 3′ end and contains a covalently attached RNA primer at its 5’ end 
(Guo et al., 2007; Nassal, 2015). To complete its life cycle, these modifications must be 
removed from rcDNA, and the gaps need to be filled and ligated to have a proper genomic 
template for transcription. The resultant completely circular genomes are called covalently 
circular closed (ccc) DNA. cccDNA is the stable nuclear form of the genome that is the 
template for all progeny genomes.
The mechanism by which rcDNA is converted into cccDNA is not fully known but, as 
discussed further below, it is believed that the host DNA repair enzymes as well as other 
cellular enzymes are used (Guo and Guo, 2015). Removal of pol from the rcDNA minus 
strand, a process called “deproteination”, is thought to be mediated by host cellular 
enzymes. These are either proteases, endonucleases and, or phosphodiesterases (Gao and 
Hu, 2007; Guo et al., 2007, 2010; Kock et al., 2010). Topoisomerases (TOP1 or TOP2) 
regulate viral DNA super-coiling by incising within one or both DNA strands and forms a 3′ 
or 5’ tyrosyl-DNA phosphodiester bond at the break sites (Champoux, 2001). Pol bound to 
minus strand of rcDNA is structurally similar to the TOPDNA adduct in terms of the 
tyrosyl-DNA phosphodiester bond. TOPDNA adducts are substrates for tyrosyl-DNA-
phosphodiesterases (TDPs), which cause a trans-esterification reaction and release of the 
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protein (Pommier et al., 2014). Recent studies have demonstrated that TDP2 can 
catalytically unlink the tyrosyl-minus strand DNA bond between pol and rcDNA in vitro, but 
the role of this enzyme in cccDNA formation in virus-replicating cells remains controversial 
(Cui et al., 2015; Koniger et al., 2014).
As mentioned above, rcDNA contains gaps, one on each strand, which need to be filled in 
and sealed for cccDNA formation. The gaps on rcDNA can be considered as two single 
strand DNA breaks and hence, induces host DNA damage and repair response which are 
then presumably exploited by the virus (Guo and Guo, 2015; Schreiner and Nassal, 2017). 
HBV pol inhibitors do not apparently prevent cccDNA formation from incoming virus, and 
thus, host polymerases and ligases are implicated in this process. Consistent with this 
reasoning, Qi et al. reported that cellular DNA polymerase κ plays a role in cccDNA 
formation during de novo HBV infection in cell cultures (Qi et al., 2016), presumably 
through filling in the gap on plus strand of the incoming viral genome. The cellular enzyme, 
flap-like structure specific endonuclease 1 (FEN 1), which is involved in cellular DNA 
replication and repair, has been reported to be involved in cccDNA formation, possibly at the 
step of removing one copy of the terminal redundant sequences from the minus strand of 
rcDNA (Kitamura et al., 2018). Furthermore, host DNA ligase 1 and 3 have been shown to 
exert overlapping functions in cccDNA formation, likely at the last step of cccDNA 
biosynthesis through covalently joining the extremities of rcDNA (Long et al., 2017). 
However, the detailed molecular mechanism and pathway for cccDNA formation awaits 
further investigation.
In addition to rcDNA, a minor portion of HBV virions contain double stranded linear (dsl) 
DNA. Sequence analysis of virus-host DNA joints and cccDNA recombinant joints have 
shown that dslDNA that can be converted into cccDNA and integrated into host chromosome 
(Bill and Summers, 2004; Yang and Summers, 1995, 1998, 1999). However, while rcDNA is 
repaired to form wild-type cccDNA, the dslDNA-derived cccDNA carries deletions or 
insertions around the site of end-joining (Yang and Summers, 1995), suggesting that rcDNA 
and dslDNA are converted into cccDNA via different DNA repair pathways. In this regard, it 
was demonstrated that Ku80 and ligase 4, the components of NHEJ DNA repair pathway, 
are essential for the formation of DHBV cccDNA from dslDNA, but not rcDNA (Guo et al., 
2012; Long et al., 2017). It should be noted that integration of viral dslDNA into the host 
chromosomes is also dependent upon NHEJ (Bill and Summers, 2004). Integration of HBV 
DNA into host chromosomes is not required for HBV replication, but it may play a role in 
viral pathogenesis (Tu et al., 2017). In woodchucks, where viremia is extremely high and 
liver cirrhosis does not often occur, the integrations appear to be a major mechanism of 
proto-oncogene activation and liver cancer (Fourel et al., 1992, 1994; Hansen et al., 1993; 
Wei et al., 1992). In patients, the contribution of integrated HBV DNA to activation of 
cellular proto-onco-genes as a mechanism of liver cancer is apparently much less common 
than in woodchucks, but can serve as a marker for clonal expansion (Mason et al., 2016). On 
the other hand, HBV genomes integrated in to host chromosomes, may be an alternative 
source of HBsAg (Wooddell et al., 2017).
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5.2. Therapeutic interference with HBV cccDNA synthesis
HBV cccDNA is the template for transcription of viral pgRNA (genomic RNA) and is thus 
essential for production of progeny production. It is stable, and is responsible for long term 
viral persistence, even after years of Pol inhibitor therapy and suppression of all detectable 
viral DNA in the circulation (Alweiss and Dandri, 2017). Thus, targeting cccDNA is 
considered the most important goal in the field of anti-HBV drug design (Alter et al., 2018). 
The host functions involved in cccDNA formation and the drugs that target them are shown 
in Fig. 3. Identification of DNA repair enzymes involved in formation of cccDNA may 
provide a new antiviral drug targets. Disubstituted sulfonamide compounds and 
hydrolyzable tannins have been identified as inhibitors of cccDNA formation by interfering 
with rcDNA deproteination (Cai et al., 2012; Liu et al., 2016), though their host or viral 
target(s) awaits further investigation.
Interferon (IFN)-α and -γ, Tumor Necrosis Factor (TNF)-α, and the activation of 
lymphotoxin (LT) β (LTβ) receptor have been shown to cause degradation of cccDNA 
through activation of nuclear APOBEC3 deaminases and subsequently inducing deamination 
and formation of an Apurinic/Apyrimidinic site in cccDNA for degradation without 
affecting the host genome (Lucifora et al., 2014; Xia et al., 2016). Thus, use of LTβ receptor 
agonists or adoptive T cell therapy might lead to receptor-mediated cccDNA degradation 
and remission of chronic HBV infection. Another cytidine deaminase, the activation-induced 
cytidine deaminase (AID), has been shown to be upregulated by both IL-1β and TNFα, and 
induce HBV DNA deamination, however, the AID-mediated anti-HBV activity is not relying 
on its deaminase activity (Watashi et al., 2013). Such deamination-independent anti-HBV 
activity has also been observed in study of APOBEC3G (Nguyen et al., 2007).
CRISPR/Cas9 is yet another tool that has emerged to target HBV cccDNA. A series of 
studies have confirmed the therapeutic effectiveness of this editing tool in targeting HBV 
DNA both in vitro and in vivo (Kennedy et al., 2015; Lin et al., 2014; Moyo et al., 2017; 
Ramanan et al., 2015; Seeger and Sohn, 2014, 2016). However, therapeutic use of CRISPR/
Cas9 faces significant challenges with respect to delivery, efficiency and safety.
6. Transcription of cccDNA and transport of RNA out of the nucleus
6.1. Biology of transcription of cccDNA and transport of RNA out of the nucleus
As indicated, cccDNA is the major template for all five viral transcripts leading to all 
progeny viral genomic DNA, and probably most viral mRNA. Recent reports suggested that 
the integrated viral HBV genome may be a significant contributor of transcripts for mRNA 
for HBsAg (S), especially in HBeAg-negative patients (Wooddell et al., 2017), although the 
clinical significance of this is not yet determined. That being said, as with cccDNA, 
transcription of HBV integrants is mediated by the host RNA pol II (Rall et al., 1983), which 
recognizes cis acting elements on the viral DNA, and represents a body of prospective host 
targeting interventions. cccDNA is complexed with cellular histone and non-histone 
proteins, assembling in to chromatin like structures, as has been called a mini-chromosome 
(Bock et al., 1994, 2001; Newbold et al., 1995). Enrichment of host RNA pol II on cccDNA 
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has been reported to be associated with active posttranscriptional modifications (PTMs) on 
ccc-DNA bound histone (Riviere et al., 2015; Zhang et al., 2017).
As shown in Fig. 4, cccDNA is transcribed into 5 major transcripts: (a) 3.5 kb preCore 
mRNA (specifies preCore polypeptide and HBeAg), (b) 3.5 kb pre-genomic(pg) RNA (the 
template for reverse transcription of viral DNA), (c) 2.4 kb specifying LHBs (L), (d) 2.1 kb 
specifying MHBs (M) and SHBs (S), and (e) 0.7 kB transcript specifying X. These 5 mRNA 
are from 4 promoters, Core, preS, S and X, with M/S coming from the S promoter.
There is evidence that splicing of HBV RNA occurs, and could lead to transcripts with 
unappreciated functions and even viral polypeptides not previously recognized (Bayliss et 
al., 2013; Su et al., 1989). Splice variants have been found in high amounts in many 
chronically infected patients. Polypeptides encoded by HBV RNA spliced variant transcripts 
have been hypothesized to play role in viral persistence (Lee GH, 2008). The significance of 
these splice variants in the normal viral life cycle is unclear, although elevations in 
circulating levels of them have been associated with increased risk of liver cancer (Bayliss et 
al., 2013). Thus, understanding the role and importance of the host-regulated splicing event 
can be another possible point of intervention for drug targets.
Since HBV cccDNA exists as a mini-chromosome, its transcription is regulated by host 
factors and subject to host epigenetic modification(s) (Hong et al., 2017). Using explants of 
human livers, a direct correlation was shown between HBV replication activity and the 
acetylation status of HBV cccDNA-bound H3 and H4 histones (Pollicino et al., 2006). 
Transcription factors ATF, YY1, p300/CBP and CREB, and proteins that modify chromatin 
such as STAT1, and EZH2 have also been implicated in regulation of HBV gene expression. 
There is active co-recruitment of cellular histone acetyltransferases-p300/CBP and PCAF/
GCN5- and the histone deacetylases (HDAC1 and hSirt1) and polycomb repressor complex 
(EZH2 and YY1) in vivo and in vitro onto cccDNA that correlate with high and low viral 
replication, respectively (Belloni et al., 2009, 2012). In other attempts to study the histone 
methylation status of cccDNA and regulation of its transcription, PRMT5 (protein 
methyltransferase 5) has been shown to induce a symmetric di-methylation of H4R3 on 
cccDNA and regulate the binding of host pol II and host Brg1-based hSW1/SNF chromatin 
remodeler contributing to the transcriptional repression RNA of cccDNA (Zhang et al., 
2017); in addition, hSirt3 was found to restrict HBV cccDNA transcription by acting 
cooperatively with histone methyltransferase SUV39H1 to decrease the recruitment of 
SETD1A, leading to a marked increase of H3K9me3 and a decrease of H3K4me3 on 
cccDNA (Ren et al., 2018).
Consistent with the liver tropism of HBV, liver “specific” transcription factors regulate 
pgRNA synthesis and activate replication. For example, HNF4 and RXRα/PPARα. HNF3β 
antagonizes the viral replication by inhibiting pgRNA synthesis in mouse NIH 3T3 
fibroblasts (Tang and McLachlan, 2001). Epigenetic changes in the cccDNA alter the 
binding of various liver-enriched transcription factors to its enhancer region. While HNF4α 
can bind to various HBV enhancer regions and promote viral transcription (Moolla et al., 
2002; Quasdorff et al., 2008; Quasdorff and Protzer, 2010), higher HNF4α expression levels 
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were seen in CHB patients whereas HNF3β levels were observed to be downregulated (Long 
et al., 2009).
Other, general transcription factors that bind to HBV promoters and enhancers include 
nuclear factor (NF1), specificity protein 1 (SP1), activator protein 1 (AP1), TATA-binding 
protein (TBP), prosperous-related homeobox protein 1(PROX1), c-AMP-response element-
binding protein (CREB), nuclear factor-kappa B (NF-kB), octane transcription factor 1 
(OCT1), and nuclear respiratory factor 1 (NRF-1). HNF1α has been shown to control HBV 
regulatory elements, such as, preS1 promoter by binding directly to it (Raney et al., 1991) 
and enhancer II (EnhII) by interacting with it through hB1F1 or B element in the enhancer 
region in cccDNA (Cai et al., 2003) and thus, regulating cccDNA transcription. HNF3α and 
HNF3β binding motifs were observed in the EnhII region and competitive binding of 
HNF3β and HNF4 was also noticed in HBV EnhII region (Li et al., 1995). HNF6 is involved 
in liver homeostasis and liver cell proliferation and has been revealed to inhibit HBV gene 
expression in HepG2 cells by suppressing preS2/S promoter activity (Hao et al., 2015). A 
liver-enriched transcription factor, C/EBP has also been demonstrated to bind to HBV 
promoters and enhancers and promote HBV transcription by transactivation of EnhII and 
synergistically activate EnhII through interaction with HBx (Lopez-Cabrera et al., 1991). 
C/EBP has also been proven to suppress core promoter (Lopez-Cabrera et al., 1990) and 
bind to enhancer I (EnhI) to repress HBV transcription (Pei and Shih, 1990). The Fox A 
transcription factors, which are critical in mediating development and tissue specific 
expression, appear to be important to the regulation of the expression of the HBV genome, 
which contains multiple FoxA binding sites. Briefly, the HBV transgene in the hepatocytes 
of FoxA deficient mice was highly methylated, and was not efficiently transcribed 
(McFadden et al., 2017). It is worth noting that the above studies are largely performed with 
transfected HBV plasmid in cell culture or transgenic HBV DNA in mice. In addition, many 
transcription factors that influence HBV cccDNA expression are also associated with host 
cell metabolism and nutrition. In this regard, CREB, HNFs and Farnesoid X receptor (FXR) 
fall in to this category, although the FXR may regulate HBV via direct affects upon viral 
functions, and by indirect affects upon bile salts (Ramiere et al., 2008; Wang et al., 1999). 
Nonetheless, the FXR deserves special attention, since a FXR agonist (EYP001) is now in 
clinical trials (Erken et al., 2018).
Methylation of CpG islands within integrated HBV DNA occurs (Miller and Robinson, 
1983) and has been correlated with HCC progression (Chen et al., 1988). CpG methylation 
within the HBV cccDNA may also contribute to viral gene regulation during viral infection, 
highlighting another system of host factors affecting the HBV genome of cccDNA, has been 
reported (Jain et al., 2015; Mogul and Schwarz, 2011; Zhang et al., 2014). Interaction of the 
HBV core protein with cccDNA has been observed to be correlated with association of host 
CREB binding protein (CBP), hypomethylation and decreased HDAC1 binding on CpG 
island of cccDNA (Guo et al., 2009).
Taken together, host epigenetic readers, writers and erasers and host cytokines play an 
important role in regulating HBV cccDNA transcription the detailed proteomics and 
epigenomics of cccDNA mini-chromosome and may provide opportunities for drug 
intervention targeting the most important HBV player, cccDNA.
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The HBV “X” (HBx) polypeptide has been reported to affect HBV cccDNA transcription 
activity by its interaction with cellular polypep-tides. Initially it was observed that p300 
recruitment to cccDNA was impaired while there was increased recruitment of HDACs, 
hSirt1 and HDAC1, in HBx mutant (cells replicating with HBx defective virus). 
Accordingly, while the HBx mutant cells didn’t show any difference in the cccDNA pool 
compared to the wild type, there was impairment of cccDNA transcription that lead to 
reduced pgRNA formation suggesting HBx’s role in epigenetic regulation of cccDNA 
transcription. Also, the kinetics of HBx recruitment was concurrent with HBV replication 
(Belloni et al., 2009; Lucifora et al., 2011).
Recently, HBx has been reported to function by recruiting the DDB1 ubiquitin ligase to 
degrade SMC5/6, a putative negative regulator of HBV transcription (Decorsiere et al., 
2016; Murphy et al., 2016). HBx has been reported to also work via AP-2, CREB, TFIIB, 
TFIH and has also been thought to oppose the cccDNA repressive activities of host protein 
Spindlin 1 and possibly to “overcome” SETDB1 mediated H3Kme3 and HP1 condensation 
of cccDNA (Riviere et al., 2015). See Fig. 4.
Cellular microRNAs (miRNAs) are another host system that may influence HBV gene 
expression and hence its life cycle. Although a direct cause and relationship between 
specific miRNAs and HBV gene expression has not been unambiguously shown, there is a 
growing body of evidence associating levels of specific miRNAs and HBV levels in people, 
as well as evidence of an interplay between HBx and a number of microRNAs (Novellino et 
al., 2012; Wei et al., 2013a, 2013b; Zhang et al., 2013). miRNA-18a prevents the expression 
of ER-α and thus inhibiting the repressive effect of ER-α on HBV replication through its 
interaction with HNF4α (Liu et al., 2009). Other miRNAs, such as, miRNA-1, 148a, 152, 
210 and 449a, have been speculated to regulate HBV replication by targeting host epigenetic 
factors-DNMT and HDAC (Braconi et al., 2010; Huang et al., 2010; Zhang et al., 2009, 
2011). A number miRNAs are known to target HBV transcripts, such as, miRNA-122, which 
is abundant in hepatocytes and targets and binds a highly conserved site on pgRNA, 
reducing the level of viral expression (Chen et al., 2011b; Qiu et al., 2010; Wang et al., 
2012). miRNA125a-5p, miRNA199–3p, miRNA210, miR-224 have all been reported to 
specifically bind HBV mRNA. miRNA-199a-3p and miRNA-125a-5p bind to the 2.1 kb 
RNA species, and miRNA-210 bind to 2.4 kb RNA species, and directly and suppress 
translation (Potenza et al., 2011; Zhang et al., 2010). Moreover, miRNA-1231 targets 
pgRNA and suppresses replication (Kohno et al., 2014). Bioinformatics analyses have also 
identified miRNA-199a-3p, miRNA-210 and miRNA-345 binding sites on 3.5 kb RNA; 
miRNA-let7, −196b and −511 binding sites on 2.4 kb RNA and miRNA-433 binding on 2.1 
kb RNA and miRNA-205 on 0.7kbRNA (Liu et al., 2009; Potenza et al., 2011; Wu et al., 
2015; Zhang et al., 2010, 2013). However, the biological significance of these binding sites 
is not firmly established.
HBV transcripts contain significant, and unusual, secondary structures, at their 5′ and near 
the 3’ ends, such as “epsilon” and PRE (post transcriptional element). Both of these 
elements may have cis functions to facilitate either transport, translation, stability and, or 
packaging in to capsids (in the case of epsilon). They are likely to interact with host 
functions that mediate these processes, and given how unusual are their structures (found 
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more often in noncoding than in coding RNAs), they may present opportunities for antiviral 
targeting. Curiously, there is evidence that HBV pregenomic RNA may use the host TRAMP 
pathway normally used for quality control and degradation of defective host transcripts, for 
its maturation (Javanbakht et al., 2017; Mueller et al., 2018; Zhou et al., 2018).
It has been reported that the host zinc finger antiviral protein (ZAP) and ribonuclease ISG20 
target the epsilon structure of HBV RNA for degradation in nucleus (Liu et al., 2017; Mao et 
al., 2013). In addition, AID has been shown to interact with HBV pol and RNA processing 
exosome to degrade HBV RNA (Liang et al., 2015a). Lastly, the nuclear export of HBV 
RNA is regulated by PRE and involves a cellular factor TAP/NXF1 (Tip-associated protein/
nuclear export factor-1) (Li et al., 2010; Lim and Brown, 2016; Yang et al., 2014).
6.2. Therapeutic interference with HBV cccDNA transcription and transcripts
Drug discovery approaches aiming to target the epigenetic enzymes are well established in 
anti-cancer therapy. The presence of upregulated acetylated H3 and H4 on cccDNA offers 
the possibility of incorporating HAT inhibitors as treatment options for chronic patients, 
although toxicity inherent in these approaches presents a challenge. Use of PRMT5 agonists 
might be another approach to repress HBV cccDNA transcription. Also, as illustrated in Fig. 
4, HBV cccDNA transcription is regulated positively and negatively by host transcription 
factors, and as the contributions of these factors become better understood, it is possible to 
imagine drugs targeting the factors upon which the virus is most, and perhaps selective 
dependent, that could have useful antiviral activity. Helioxanthin analogues, for example, 
have been shown to have a potent antiviral effect in hepatoma cells stably producing HBV 
by down-regulation of critical transcription factors (Ying et al., 2007). Again, of course, the 
major concern with histone and transcriptional modifiers is their selectivity, or possible lack 
thereof, for viral functions.
IFN-α treatment, in vitro, using HBV producing hepatoma cells and, in vivo, using mouse 
models, repressed HBV cccDNA transcription (Belloni et al., 2012). In cell-based systems, 
IFN-α, has been shown to suppress HBV cccDNA transcription by promoting recruitment of 
HDAC1 to HBV mini-chromosome and reducing the acetylation of cccDNA-associated 
histone H3 lysine 9 (H3K9) and 27 (H3K27) (Belloni et al., 2009; Liu et al., 2013).
Exploiting the ability of SMC5/6 to repress HBV cccDNA, is certainly worth exploring, 
possibly by way of inhibiting the HBx poly-peptide, since HBx was reported to oppose the 
SMC5/6-mediated repression of HBV cccDNA (Decorsiere et al., 2016; Murphy et al., 
2016).
Recently, we and others have reported that a small molecule, a dihydroxyquinoline, can 
cause the rapid degradation of HBV transcripts (Mueller et al., 2018; Zhou et al., 2018). The 
degradation occurs in the nucleus, and is selective, to the extent that most other host 
transcripts and proteins tested are not significantly affected, over the period of study. The 
drug’s action requires that the viral transcript contain the highly structured PRE region, 
which could be the basis for a viral selectivity. However, the PRE hair pin structures are 
similar to sub sets of noncoding cellular RNAs, suggesting that host functions may also be 
targeted by this compound. The ultimate clinical usefulness of this approach remains to be 
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seen, but these data certainly establish the principle of targeting viral RNA stability and 
transport for selective antiviral therapy.
7. HBV RNA translation, capsid formation, pgRNA encapsidation and 
reverse transcription
7.1. HBV RNA translation, capsid formation, pgRNA encapsidation and reverse 
transcription
There are at least 5 HBV mRNA species that translate 7 HBV proteins (see Introduction) in 
cytoplasm by using cellular translation machinery. Production of HBV e antigen (HBeAg) is 
mediated by a host furin endopeptidase that cleaves the C-terminus of HBeAg precursor, 
preCore protein, and the product (HBeAg) is secreted into the serum (Ito et al., 2009).
As indicated in Fig. 5, Core and pol are translated from the same mRNA, the pgRNA (Ou et 
al., 1990). There are 240 core proteins in every capsid, and only one pol. Thus, it is likely 
that the translation efficiencies of Core and pol are regulated by host, as well as viral, 
factors. Due to the bicistronic nature of Core and pol ORFs within pgRNA, translation of pol 
occurs by more than one mechanism. The majority of pol is translated by re-initiation at the 
first AUG after translation termination of a mini-cistron that is translated from the second 
AUG between the Core and Pol ORFs (Hwang and Su, 1998). Pol translation is also initiated 
via at least two mechanisms: (i) leaky scanning through the four AUGs between core and pol 
ORFs and (ii) backward scanning to the pol AUG after translation termination of the core 
ORF (Sen et al., 2004).
HBV core protein is ~183–185 amino acid (aa) long, depending on the genotype, and forms 
dimers and multimers which are assembled into the capsid (Gallina et al., 1989; Nassal, 
1992; Zlotnick et al., 1997). The C-terminal domain (CTD) of core has serine-
phosphorylation sites, which are substrates for host kinases. This phosphorylation correlate 
with pgRNA encapsidation and the subsequent dephosphorylation has been concurrent with 
capsid maturation, envelopment and egress from the cell (Lan et al., 1999; Melegari et al., 
2005; Perlman and Hu, 2003). The host cellular kinases involved include cdc2-like kinase, 
CDK2, Polo-like-kinase 1 (PLK-1), Protein kinase C-α (PKC-α), SRPK1 and SRPK2 
(Barrasa et al., 2001; Daub et al., 2002; Diab et al., 2017; Kann and Gerlich, 1994; Kau and 
Ting, 1998; Ludgate et al., 2012). However, the detailed roles of the above-mentioned 
kinases need to be further characterized. Wittkop et al. showed that inhibition of PKC-α 
doesn’t affect genome maturation but hinders virion formation and leads to capsid 
accumulation due to defects in the latter’s development (Wittkop et al., 2010). SRPK1 is 
also considered to gate and help in capsid assembly (Chen et al., 2011a). NIRF (Np95/
ICBP90-like ring finger protein) is an ubiquitin ligase that interacts with the core protein to 
regulate its half-life, and causes its proteosomal degradation and destabilizes the capsid 
(Qian et al., 2012). Along the same lines, while Hsp90 interacts with the core to stabilize the 
capsid, Hsp40 is yet another chaperone protein that antagonizes this protein-protein 
interaction to destabilize capsid and also degrades HBx protein (Shim et al., 2011; Sohn et 
al., 2006). Whether HBV capsid assembly occurs in a specific cell compartment is largely 
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unknown, but a recent study indicates that an intact cellular microtubule network is required 
for capsid formation (Iwamoto et al., 2017).
After translation, in-situ binding of pol to epsilon (ε) stem-loop structure of pgRNA inhibits 
viral translation and triggers nucleocapsid assembly by specific incorporation of both 
pgRNA and pol into viral capsids, which is called pgRNA encapsidation (Ryu et al., 2008, 
2010; Seeger and Mason, 2000). The proper folding of pol and its binding to pgRNA are 
assisted by host chaperons including HSP90 and its cofactors (Hu et al., 2002). HBV DNA 
replication exclusively takes place in viral nucleocapsid, where the pgRNA is reverse 
transcribed into rcDNA by pol (Nassal, 2008). Several host proteins have been shown to be 
packaged into HBV nucleocapsid via interaction with pol and potentially regulate the 
reverse transcription, including eIF4E, DDX3, APOBEC3G, etc (Kim et al., 2010; Nguyen 
and Hu, 2008; Wang et al., 2009).
7.2. Therapeutic interference with HBV RNA translation, capsid formation and pgRNA 
encapsidation and reverse transcription
At present, there are 5 Direct Acting Antiviral (DAA) polymerase inhibitors (Liang et al., 
2015b). As indicated in this review, it is possible, in theory, to inhibit the viral reverse 
transcriptase by targeting host functions, and drugs that affect cell chaperons involved in 
reverse transcription have shown to be antiviral. Indeed, interference with any of the host 
proteins involved in capsid and virion formation, could have antiviral activity. Hsp90 
inhibitors have been gaining importance in cancer treatment for its potential for 
combinatorial targeting of multiple oncogenic protein pathways. Since Hsp90 is involved in 
pol-ε complex formation and Hsp90-Core interaction stabilizes the capsid, it is possible that 
Hsp90 small molecule inhibitors, such as geldanamycin and radicicol (natural products) as 
well as the semisynthetic derivatives 17-N-Allylamino-17-demethoxygeldanamycin 
(17AAG), could have anti-HBV potential. Hsp40 analogues or agonists might also be 
employed to reduce the stability of the capsid, by causing degradation of HBc and HBx 
proteins (Sohn et al., 2006). Moreover, since HBx has been shown to regulate the 
transcription of cccDNA, Hsp40 analogues may also inhibit cccDNA transcription.
Various kinase inhibitors are presently employed in the field of cancer treatment, and thus 
kinase inhibition is well established. For HBV intervention, since phosphorylation of core 
plays a role in regulating capsid formation and nucleocapsid maturation, inhibition of the 
host kinases involved is a possible antiviral strategy. Butyrolactone I is a selective inhibitor 
of CDK2 and cdc2 kinase (Kitagawa et al., 1993), and has been used in management of 
cancer. Several other small molecule kinase inhibitors specific for PKC-α and cdc-2, which 
mediate capsid formation, are now commercially available. However, as with any host 
targeting strategy, toxicity is always a concern. Encouragingly, administration of PLK-1 
inhibitor BI-2536 to HBV-infected humanized liver FRG mice strongly inhibited HBV 
infection, and the compound was safely tolerated by the animals (Diab et al., 2017).
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8. Envelope protein synthesis, viral particle assembly and egress
8.1. Biology of envelope protein synthesis, viral particle assembly and egress
Hepatitis B surface polypeptides (the envelope proteins) are translated from 2 species of 
mRNA (2.1 and 2.4 kb). There are 3 envelope polypeptides, the “large”, 42 kD LHBs (L) 
middle sized 33 kD MHBs (M) and the most abundant, small 26 kD, SHBs (S) polypeptide. 
They are expressed from a single open reading frame, with alternate start codons. L is 
translated from the 2.4 kb mRNA, and S and M from the 2.1 kb mRNA. The S polypeptide 
is secreted from the cell in far greater amounts than are L and M. The envelope polypeptides 
are N-glycosylated. Glycosylation and possibly other post-translational modifications play 
key roles in morphogenesis and secretion of the virions and subviral particles (Lu et al., 
1995; Mehta et al., 1997; Werr and Prange, 1998).
In addition to a common N glycosylation site on all 3 polypeptides, M possesses a second N-
glycan and an O-glycan site near its N-terminus, and this plays a role in its folding. 
Following synthesis and N-glycosylation, envelope polypeptides “oligomerize” at the ER/
ERGIC membranes, with spherical sub viral particles apparently returning to the Golgi for 
possibly further processing and secretion. Folding of M and L envelope proteins are 
dependent upon N-glycan processing, host chaperone proteins, such as heat shock protein 
(Hsp) 70 and ER resident proteins BiP and calnexin (Fig. 6). Maturation of S may be 
independent of at least N-glycan processing and calnexin, but still involves the ER luminal 
protein, protein disulfide isomerase (PDI) that seems to monitor the disulfide linkages for 
cross-linking of S chains during envelope assembly (Prange, 2012).
HBV is thought to exploit the Multi Vesicular Body (MVB) machinery for virion maturation 
and egress (Rost et al., 2008). HBV envelope proteins have been found to co-localize with 
Class E MVB proteins- AIP1/ALIX and VPS4B- in hepatoma cells through 
immunofluorescence and a dominant negative (DN) AIP1 mutant inhibited production 
and/or release of enveloped virions without significant effects on intracellular nucleocapsid 
formation, whereas DN VPS4B inhibited both nucleocapsid production and budding. By 
contrast, DN AIP1 and VPS4 had no effect on the efficiency of release of HBV subviral 
particles, which are secreted via the ER-Golgi constitutive secretory pathway (Watanabe et 
al., 2007). Lambert et al. used DN ESCRT III mutant proteins (CHMPs) and ATPase 
defective Vps4A and B to show that the expression of these defective mutant players of 
MVB inhibited virus assembly and release (Lambert et al., 2007). The E3 ubiquitin ligase- γ
−2 adaptin of the AP-I complex have been identified as important players in MVB-mediated 
HBV assembly and egress. Indeed, HBV core and L protein have been found to co-localize 
with γ−2 adaptin in the late endosomal compartments and disruption of HBV/γ2-adaptin 
interactions inhibits virus production. While depletion of γ−2 adaptin inhibited HBV release 
(Rost et al., 2006), overexpression of the adapter produced similar results, as observed with 
mutant MVB proteins-entrapment of HBV core and L protein in detergent-insoluble 
compartments (Lambert et al., 2007). NEDD4 has been shown to interact with HBV core 
protein in vivo through PPAY motif (thought to be exposed on the capsid as seen by cryo-
EM) through co-immunoprecipitation and generating PPAY sequence mutant (Rost et al., 
2008). HBV has also been found to utilize the ESCRT-II complex, comprised of EAP20, 
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EAP30, and EAP45, for secretion (Prange, 2012). Thus, HBV exploits various ubiquitin 
receptors together with endosomal sorting pathway functions for egress from hepatocytes.
Autophagy may be involved in the HBV life cycle. Both the viral X protein and the S 
envelope proteins have been reported to be inducers of autophagy and found in close 
association with LC3, an autophagosomal membrane protein (Li et al., 2011; Sir et al., 
2010). Thus, it seems possible that the HBV envelope proteins may use autophagic pathways 
in their transport to the endosomal system. In line with this notion, GTPase Rab7 has been 
identified as a central regulator of HBV transport and secretion. HBV precore protein has 
been shown to enhance Rab7 activity causing tubulations of MVB and autophagic 
compartments and interaction between the former mentioned two compartments with 
lysosomes and thus regulating its own secretion. Depletion of Rab7 or inhibition of 
lysosome function caused an increase in HBV secretion (Inoue et al., 2015). It is worthwhile 
to note that cellular lipids and sterols are also implication in virion secretion, and inhibitors 
of HMG CoA reductase have been reported to inhibit virion secretion. S has been reported to 
require cholesterol (synthesized by HMG CoA reductase) for its secretion without affecting 
the release for Dane particles (Lin et al., 2003). The budding and egress of HBV respects 
cell polarity, favoring egress in to the basal membranes (in to the circulation) and not cell to 
cell and not into the bile (Bhat et al., 2011).
Taken together, host factors are clearly critical for morphogenesis and exit of subviral 
particles and enveloped infectious virions from the cell. However, the pathway used for 
infectious virion and sub viral particle secretion are distinct, at least functionally. While γ−2 
Adaptin, Nedd4, ESCRT II, III and vsp4 are essential for virion secretion, they are 
dispensable for subviral secretion. It is therefore conceivable that drugs can be found that 
selectively repress one, but not the other, pathway. Identifying the exact route and the factors 
involved in the secretion pathway of different kinds of viral particles can help us better 
understand the egress of the virus and will prove a better outlook towards designing drugs to 
inhibit the egress.
8.2. Therapeutic interference with HBV morphogenesis
Cyclophilin A (Cyp A) has been identified as a binding partner for S-protein and is 
speculated to help in envelope assembly and release through interaction with the proline 
residues on the first cytosolic loop of S (Tian et al., 2010). Therefore, cyclophilin inhibitors, 
such as CRV431 and alisporivir have been proposed as antiviral agents (Phillips et al., 2015; 
Trepanier et al., 2017).
S protein has also been shown to associate with LC3 autophagosomal protein, indicating use 
of the host autophagy machinery in viral envelopment (Li et al., 2011). Autophagy was also 
reported to be required for HBV replication (Sir et al., 2010). Autophagy inhibitors may be 
useful against HBV.
Glucosidase inhibitors have been shown to have anti-HBV effect by inhibiting envelope 
protein glycosylation processing (the removal of terminal glucose residues from the N-
glycan on the polypeptide) in the ER and thereby, inhibiting viral morphogenesis and 
infectivity in vitro and in the woodchuck model (Block et al., 1998).
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9. Conclusion and perspective
Viruses interact with many host cellular pathways to achieve their replication cycle. Entry 
into the host cell, transport to the viral replication sites or viral exit from the host cell are all 
steps that require specific interactions between the virus and its host. Additionally, the 
evasion from the host immune response requires a lot of viral proteins to associate with and 
inhibit cellular proteins with antiviral functions. Viruses display remarkable specificity in 
both the host species and the cell types that they infect. Understanding this specificity 
reveals insight into the basic host components that are required for the viral life cycle and 
host restriction factors that limit the virus. HBV is a small virus, encoding only four open 
reading frames. Because it is so compact it must be adapted to its host to take full advantage 
of host systems, something commonly seen in viruses. Consequently, HBV proteins must be 
multi-functional. In this review we tried to identify the different host factors that interact and 
effect HBV as it proceeds along its life cycle starting from its entry to a cell-specific 
receptor to egress of new viral particles. While there are host restriction and immune factors 
that work towards fighting against the infection, the virus utilizes the basic host machinery 
to sustain within the host cell. We emphasize the toxicity concerns inherent in an 
intervention that targets host functions, and have taken care to distinguish between 
compounds that target host functions but serve only as research tools, and compounds that 
have promise as therapeutic leads. This review aims at identifying feasible druggable targets 
that helps us take a step forward towards understanding HBV-host interaction and working 
towards fighting the infection especially in cases of chronic patients. Combination therapy 
might be the best way to move forward considering the very limited treatment options and 
development of viral resistance to existing drugs. Thus, using different approaches to target 
the virus directly or proviral host factors at more than one step along the viral life cycle 
might be the future of HBV treatment. While the path to understanding and targeting host 
factors as antivirals have been less traveled and significant challenges remain, delivering the 
most effective antiviral regimen, including both host and viral targets, should be well worth 
the effort.
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Fig. 1. Binding to and entry in to hepatocytes.
The hepatitis B virion is shown in (A) making an initial “docking” on to heparin sulfate 
proteoglycans (HSPG), followed by (B) “rolling” to Sodium Taurocholate Polypeptide 
(NTCP) receptors, which are believed to be the higher affinity receptor for the virus. Cellular 
functions mediating these steps are indicated in orange, research phase compounds that 
interfere with these steps are shown in pinkish red, with compounds that are clinical phase, 
or approved, in light blue. This scheme was illustrated by using the Biology Bundle of 
Motifolio Drawing Toolkits (www.motifolio.com) (the same as following figures). (For 
interpretation of the references to colour in this figure legend, the reader is referred to the 
Web version of this article.)
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Fig. 2. Transport of the virus nucleocapsid to the nucleus.
Following entry in to the cell, the virus is de-enveloped and the nucleocapsid is transported 
to the nucleus. Cellular functions mediating these steps are indicated in orange, research 
phase compounds that interfere with these steps are shown in pinkish red, with compounds 
that are clinical phase, or approved, in light blue. (For interpretation of the references to 
colour in this figure legend, the reader is referred to the Web version of this article.)
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Fig. 3. Deproteination of the viral DNA, and synthesis of viral cccDNA.
The viral polymerase protein within the capsid is covalently attached to the 5′ end of 
“minus” strand of DNA, and must be removed for the successful production of covalently 
closed circular DNA (cccDNA), which is the template for all viral transcripts in the normal 
infection (shown as the 3 interlocked circles). The host functions mediating this process are 
not definitively known, but TDP2 may be involved. Host polymerase kappa (polK), FEN1, 
and DNA ligase (LIG) 1 and 3 are needed to complete the formation of cccDNA. 
Topoisomerases and various DNA repair functions may be involved. Cellular functions 
mediating these steps are indicated in orange, research phase compounds that interfere with 
these steps are shown in pinkish red, with compounds that are clinical phase, or approved, in 
light blue. (For interpretation of the references to colour in this figure legend, the reader is 
referred to the Web version of this article.)
Mitra et al. Page 31
Antiviral Res. Author manuscript; available in PMC 2018 October 18.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Fig. 4. Transcription of cccDNA and transport of viral RNA out of the nucleus.
HBV cccDNA is associated with, and presumably regulated by numerous host 
transcriptional factors, and unmodified and modified histones. Host SMC5/6 complex is 
shown, in this illustration, “attacking” (and transcriptionally repressing) HBV cccDNA, with 
HBx binding host protein DBB1 which, causes the degradation of SMC5/6, and thus 
promotes HBV cccDNA transcription. Host pol II transcribes HBV cccDNA as well as HBV 
DNA integrated in to the host chromosomes, and these transcripts are processed and 
transported out of the nucleus using numerous host functions, including polyadenylation, 
although the precise pathways of processing are not well established. Cellular functions 
mediating these steps are indicated in orange, research phase compounds that interfere with 
these steps are shown in pinkish red, with compounds that are clinical phase, or approved, in 
light blue. (For interpretation of the references to colour in this figure legend, the reader is 
referred to the Web version of this article.)
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Fig. 5. HBV RNA translation, capsid formation, encapsidation, reverse transcription and 
recycling of the nucleocapsid to the nucleus.
Five main species of HBV mRNA are translated in the cytoplasm in to the viral polypeptides 
precore (precursor of HBeAg, from the 3.5 kb precore mRNA), core and pol (from the 3.5 
kb pgRNA), envelope polypeptides L (from the 2.4 kb mRNA), envelope polypeptide, M 
and S (from the 2.1 kb mRNA) and X from the 0.7 kb mRNA. Core rapidly dimerizes, is 
modified by phosphorylations, and cooperates with pol and pgRNA to form the 
nucleocapsid. Host factors modulate translation, phosphorylation, and even folding through 
chaperons of the viral functions. Encapsidated viral pgRNA is reverse transcribed, and 
nucleocapsids are either enveloped and secreted (see Fig. 6), or not enveloped and recycled 
to the nucleus, where they may then begin the cycle of cccDNA production, and 
transcription of new viral gene products. Cellular functions mediating these steps are 
indicated in orange, research phase compounds that interfere with these steps are shown in 
pinkish red, with compounds that are clinical phase, or approved, in light blue. (For 
interpretation of the references to colour in this figure legend, the reader is referred to the 
Web version of this article.)
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Fig. 6. Morphogenesis, envelopment and secretion of HBV.
Nucleocapsids associated with newly synthesized, envelope polypeptides, S, M, and L, 
which would have been co- and post-translationally modified by N-glycosylations and 
glycan processing (L, M, S) and O-glycosylation (M), and myristolyation (L). M, and 
possibly L, are “folded” by Calnexin, and BiP. L, M and S are all heavily disulfide bonded, 
are use Protein Disulphide Isomerase (PDI) is their maturation. Numerous cell functions 
mediate vesicle transport. Subviral particles of oligomerized S bud in to the lumen of the 
ER-Golgi and are secreted out of the cell via constitutive secretory mechanisms. 
Envelopment of nucleocapsids, to form virions, probably occurs at the ER and then a Multi 
Vesicular Body (MVP). MVP derived exosomes containing enveloped virions are thought to 
fuse with plasma membranes and result in virion release in to the blood. Note that this 
occurs in a “polarized” hepatocyte, in which secretion of virions is through the basolateral 
side of the cell. Cellular functions mediating these steps are indicated in orange, research 
phase compounds that interfere with these steps are shown in pinkish red, with compounds 
that are clinical phase, or approved, in light blue. (For interpretation of the references to 
colour in this figure legend, the reader is referred to the Web version of this article.)
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